Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...
Sino Biopharmaceutical
Sino Biopharmaceutical’s TQ-B3525 Files for Market Approval with CDE
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a market approval filing for its Category 1...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...
Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...
Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...
F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline
The acquisition of UK-based biologics firm F-Star Therapeutics (NASDAQ: FSTX) by China’s Sino Biopharmaceutical (HKG:...
Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...
Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...
XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development
Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
Sino Biopharmaceutical Reports Mixed Results in 2022 Interim Report
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has released its 2022 interim report, recording revenues of...
Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...